@article{1c567b4e80644aeb9355818b0938fabf,
title = "Insights into pediatric rhabdomyosarcoma research: Challenges and goals",
abstract = "Overall survival rates for pediatric patients with high-risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan.",
keywords = "cancer biology, early-phase clinical trials, genomics, rhabdomyosarcoma",
author = "Yohe, {Marielle E.} and Heske, {Christine M.} and Elizabeth Stewart and Adamson, {Peter C.} and Nabil Ahmed and Antonescu, {Cristina R.} and Eleanor Chen and Natalie Collins and Alan Ehrlich and Galindo, {Rene L.} and Gryder, {Berkley E.} and Heidi Hahn and Sharon Hammond and Hatley, {Mark E.} and Hawkins, {Douglas S.} and Hayes, {Madeline N.} and Andrea Hayes-Jordan and Helman, {Lee J.} and Simone Hettmer and Ignatius, {Myron S.} and Charles Keller and Javed Khan and Kirsch, {David G.} and Linardic, {Corinne M.} and Lupo, {Philip J.} and Rossella Rota and Shern, {Jack F.} and Janet Shipley and Sivasish Sindiri and Tapscott, {Stephen J.} and Vakoc, {Christopher R.} and Wexler, {Leonard H.} and Langenau, {David M.}",
note = "Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",
year = "2019",
month = oct,
doi = "10.1002/pbc.27869",
language = "English (US)",
volume = "66",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "10",
}